Literature DB >> 12270844

Evidence-based risk stratification to target therapies in acute coronary syndromes.

Christopher P Cannon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12270844     DOI： 10.1161/01.cir.0000030416.80014.f4

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  6 in total

1.  Medication errors in patients with severe chronic kidney disease and acute coronary syndrome: the impact of computer-assisted decision support.

Authors:  Richard V Milani; Sylvia A Oleck; Carl J Lavie
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

Review 2.  Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond.

Authors:  S J Walsh; M S Spence; D Crossman; A A J Adgey
Journal:  Heart       Date:  2005-09       Impact factor: 5.994

3.  Plasma Myeloperoxidase and Total Sialic Acid as Prognostic Indicators in Acute Coronary Syndrome.

Authors:  Sumitra Govindarajan; Vm Mithun Raghavan; Anand C Vasudeva Rao
Journal:  J Clin Diagn Res       Date:  2016-08-01

4.  Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18.

Authors:  David A Morrow; Marc S Sabatine; Marie-Luise Brennan; James A de Lemos; Sabina A Murphy; Christian T Ruff; Nader Rifai; Christopher P Cannon; Stanley L Hazen
Journal:  Eur Heart J       Date:  2008-03-12       Impact factor: 29.983

5.  An Asian validation of the TIMI risk score for ST-segment elevation myocardial infarction.

Authors:  Sharmini Selvarajah; Alan Yean Yip Fong; Gunavathy Selvaraj; Jamaiyah Haniff; Cuno S P M Uiterwaal; Michiel L Bots
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

6.  Prospective validation of the Dante Pazzanese risk score in non-ST-segment elevation acute coronary syndrome.

Authors:  Elizabete Silva Dos Santos; Luiz Minuzzo; Roberta de Souza; Ari Timerman
Journal:  Arq Bras Cardiol       Date:  2013-08-14       Impact factor: 2.000
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.